ROBERTS ZACHARY (EVP of R&D) sold 5.8% of their position (35.70K shares) of ALLOGENE THERAPEUTICS, INC. on the open market
Open‑market sale worth $63.2K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 2/4/2026ACC: 0001737287-26-000002
Officer· EVP of R&D
Since Feb 2026
+886.37K
Net shares
Net buyer
$63.2K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
922.07K acquired · 35.70K disposed
Non-Derivative Transactions1
Common Stock
Direct
Shares
−35.70K
Price / share
$1.77
Trade value
$63.19K
% of position
5.8%
2/2/2026
616.87K→581.17K
Total
Net shares
−35.70K
Net value
-$63.19K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/2/2026 | S · Sale | −35.70K | $1.77 | $63.19K | 5.8% | 616.87K | 581.17K |
| Total | −35.70K | -$63.19K | ||||||
Derivative Transactions2
Stock Option (Right to buy)
Direct
Converts to
Common Stock
718.76K shares
Shares
+718.76K
Strike price
1.87
Held after
718.76K
Exercisable
—
2/2/2026
Restricted Stock Unit
Direct
Converts to
Common Stock
203.31K shares
Shares
+203.31K
Strike price
Held after
203.31K
Exercisable
—
2/2/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy) Direct | Common Stock718.76K shares | 2/2/2026 | A · Award | +718.76K | 1.87 | — | 718.76K |
| Restricted Stock Unit Direct | Common Stock203.31K shares | 2/2/2026 | A · Award | +203.31K | — | 203.31K |